Table 26 (abstract P69). Patient and control characteristics at first dose of VZV-vaccine
From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one
Patients (n = 54) | Healthy controls (n = 18) | |
|---|---|---|
Disease type | N/A | |
Systemic JIA | 11 (20%) | |
Oligo JIA | 9 (17%) | |
Poly JIA | 22 (41%) | |
JScl | 5 (9%) | |
JDM | 7 (13%) | |
Age at vaccination (median, range) | 5 (0–20) | 8.5 (3–18) |
Medication use | N/A | |
MTX | 98% | |
MTX dose (median, range) | 15 (10–27) | |
Corticosteroids | 43% | |
Steroid dose (median, range) | 6 (3–20) | |
Biologics | 6% | |
Responder | 17 | 6 |
Nonresponder | 18 | 12 |